{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:28:04Z","timestamp":1773044884614,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1038\/s41390-022-02268-5","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T06:04:46Z","timestamp":1661925886000},"page":"1546-1550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Can T-cell and B-cell excision circles predict development of inhibitors in pediatric hemophilia A?"],"prefix":"10.1038","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3971-0336","authenticated-orcid":false,"given":"Sarina","family":"Levy-Mendelovich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atar","family":"Lev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einat","family":"Avishai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Budnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rima","family":"Dardik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asaaf Arie","family":"Barg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raz","family":"Somech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"2268_CR1","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"VS Blanchette","year":"2014","unstructured":"Blanchette, V. S. et al. Definitions in hemophilia: communication from the SSC of the ISTH. J. Thromb. Haemost. 12, 1935\u20131939 (2014).","journal-title":"J. Thromb. Haemost."},{"issue":"12 Sup","key":"2268_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","volume":"6","author":"J Oldenburg","year":"2006","unstructured":"Oldenburg, J. & Pavlova, A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 6(12 Sup), 15\u201322 (2006).","journal-title":"Haemophilia"},{"key":"2268_CR3","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/79549","volume":"6","author":"MD Hazenberg","year":"2000","unstructured":"Hazenberg, M. D. et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat. Med. 6, 1036\u20131042 (2000).","journal-title":"Nat. Med."},{"key":"2268_CR4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s10875-011-9526-6","volume":"31","author":"F Serana","year":"2011","unstructured":"Serana, F. et al. Thymic and bone marrow output in patients with common variable immunodeficiency. J. Clin. Immunol. 31, 540\u2013549 (2011).","journal-title":"J. Clin. Immunol."},{"key":"2268_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/pbc.26646","volume":"64","author":"S Levy-Mendelovich","year":"2017","unstructured":"Levy-Mendelovich, S. et al. Quantification of specific T and B cells immunological markers in children with chronic and transient ITP. Pediatr. Blood Cancer 64, 12 (2017).","journal-title":"Pediatr. Blood Cancer"},{"key":"2268_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12026-014-8558-4","volume":"61","author":"D Machnes-Maayan","year":"2014","unstructured":"Machnes-Maayan, D. et al. Insight into normal thymic activity by assessment of peripheral blood samples. Immunol. Res. 61, 198\u2013205 (2014).","journal-title":"Immunol. Res."},{"key":"2268_CR7","doi-asserted-by":"publisher","first-page":"e30494","DOI":"10.1371\/journal.pone.0030494","volume":"7","author":"A Lev","year":"2012","unstructured":"Lev, A. et al. The kinetics of early T and B cell immune recovery after bone marrow transplantation in RAG-2-deficient SCID patients. PLoS One 7, e30494 (2012).","journal-title":"PLoS One"},{"key":"2268_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/ACI.0b013e32834c233a","volume":"11","author":"R Somech","year":"2011","unstructured":"Somech, R. T-cell receptor excision circles in primary immunodeficiencies and other T-cell disorders. Curr. Opin. Allergy Clin. Immunol. 11, 517\u2013524 (2011).","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"2268_CR9","doi-asserted-by":"publisher","first-page":"215308","DOI":"10.6064\/2012\/215308","volume":"2012","author":"CS Hampe","year":"2012","unstructured":"Hampe, C. S. B cells in autoimmune diseases. Scientifica 2012, 215308 (2012).","journal-title":"Scientifica"},{"key":"2268_CR10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10875-011-9580-0","volume":"31","author":"N Amariglio","year":"2011","unstructured":"Amariglio, N. et al. T-cell compartment in synovial fluid of pediatric patients with JIA correlates with disease phenotype. J. Clin. Immunol. 31, 1021\u20131028 (2011).","journal-title":"J. Clin. Immunol."},{"key":"2268_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1084\/jem.20042251","volume":"201","author":"S Yurasov","year":"2005","unstructured":"Yurasov, S. et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201, 703\u2013711 (2005).","journal-title":"J. Exp. Med."},{"key":"2268_CR12","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1084\/jem.20042321","volume":"201","author":"J Samuels","year":"2005","unstructured":"Samuels, J., Ng, Y. S., Coupillaud, C., Paget, D. & Meffre, E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J. Exp. Med. 201, 1659\u20131667 (2005).","journal-title":"J. Exp. Med."},{"key":"2268_CR13","doi-asserted-by":"publisher","first-page":"261470","DOI":"10.1155\/2012\/261470","volume":"2012","author":"A Lev","year":"2012","unstructured":"Lev, A. et al. Characterizing T cells in SCID patients presenting with reactive or residual T lymphocytes. Clin. Dev. Immunol. 2012, 261470 (2012).","journal-title":"Clin. Dev. Immunol."},{"issue":"12 Suppl","key":"2268_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1365-2516.2006.01261.x","volume":"3","author":"J Astermark","year":"2006","unstructured":"Astermark, J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 3(12 Suppl), 52\u201360 (2006).","journal-title":"Haemophilia"},{"key":"2268_CR15","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/0140-6736(92)91324-2","volume":"339","author":"R Ljung","year":"1992","unstructured":"Ljung, R., Petrini, P., Lindgren, A. C., Tengborn, L. & Nilsson, I. M. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339, 1550 (1992).","journal-title":"Lancet"},{"key":"2268_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bcmd.2018.02.003","volume":"71","author":"H Luna-Z\u00e1izar","year":"2018","unstructured":"Luna-Z\u00e1izar, H. et al. F8 inversions of introns 22 and 1 confer a moderate risk of inhibitors in Mexican patients with severe hemophilia A. Concordance analysis and literature review. Blood Cells Mol. Dis. 71, 45\u201352 (2018).","journal-title":"Blood Cells Mol. Dis."},{"key":"2268_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12016-009-8118-1","volume":"37","author":"K Ghosh","year":"2009","unstructured":"Ghosh, K. & Shetty, S. Immune response to FVIII in hemophilia A: an overview of risk factors. Clin. Rev. Allergy Immunol. 37, 58\u201366 (2009).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"2268_CR18","doi-asserted-by":"publisher","first-page":"e142906","DOI":"10.1172\/JCI142906","volume":"131","author":"BS Doshi","year":"2021","unstructured":"Doshi, B. S. et al. B cell-activating factor modulates the factor VIII immune response in hemophilia A. J. Clin. Invest. 131, e142906 (2021).","journal-title":"J. Clin. Invest."},{"key":"2268_CR19","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi, F. et al. RandomizeD TRIAL OF FActor VIII and neutralizing antibodies in hemophilia A. N. Engl. J. Med. 374, 2054\u20132064 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2268_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/hae.12790","volume":"22","author":"M Carcao","year":"2016","unstructured":"Carcao, M., Re, W. & Ewenstein, B. The role of previously untreated patient studies in understanding the development of FVIII inhibitors. Haemophilia 22, 22\u201331 (2016).","journal-title":"Haemophilia"},{"key":"2268_CR21","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/j.1538-7836.2005.01375.x","volume":"3","author":"GC White II","year":"2005","unstructured":"White, G. C. II, Kempton, C. L., Grimsley, A., Nielsen, B. & Roberts, H. R. Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs? J. Thromb. Haemost. 3, 1676\u20131681 (2005).","journal-title":"J. Thromb. Haemost."},{"key":"2268_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/BF00172063","volume":"41","author":"HG Rammensee","year":"1995","unstructured":"Rammensee, H. G., Friede, T. & Stevanoviic, S. MHC ligands and peptide motifs: first listing. Immunogenetics 41, 178\u2013228 (1995).","journal-title":"Immunogenetics"},{"key":"2268_CR23","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1055\/s-0038-1649954","volume":"74","author":"R Schwaab","year":"1995","unstructured":"Schwaab, R. et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb. Haemost. 74, 1402\u20131406 (1995).","journal-title":"Thromb. Haemost."},{"key":"2268_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1055\/s-0038-1655944","volume":"77","author":"CR Hay","year":"1997","unstructured":"Hay, C. R. et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe hemophilia A. A UKHCDO Inhibitor Working Party. Thromb. Haemost. 77, 234\u2013237 (1997).","journal-title":"Thromb. Haemost."},{"key":"2268_CR25","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1177\/0300060519860329","volume":"47","author":"AMR Abdulqader","year":"2019","unstructured":"Abdulqader, A. M. R., Mohammed, A. I. & Rachid, S. Polymorphisms in the cytotoxic T lymphocyte-associated protein-4 immune regulatory gene and their impact on inhibitor development in patients with hemophilia A. J. Int. Med. Res. 47, 4981\u20134992 (2019).","journal-title":"J. Int. Med. Res."},{"key":"2268_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1744-313X.2009.00893.x","volume":"37","author":"D Chaves","year":"2010","unstructured":"Chaves, D., Belis\u00e1rio, A., Castro, G., Santoro, M. & Rodrigues, C. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A. Int J. Immunogenet 37, 79\u201382 (2010).","journal-title":"Int J. Immunogenet"},{"key":"2268_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-1-4613-0331-2_3","volume":"386","author":"LW Hoyer","year":"1995","unstructured":"Hoyer, L. W. The incidence of factor VIII inhibitors in patients with severe hemophilia A. Adv. Exp. Med. Biol. 386, 35\u201345 (1995).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2268_CR28","first-page":"80","volume":"37","author":"KP Pratt","year":"2009","unstructured":"Pratt, K. P. & Thompson, A. R. B-cell and T-cell epitopes in anti-factor VIII immune responses. Rev. Bras. Hematol. Hemoter. 37, 80\u201395 (2009).","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"2268_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.5581\/1516-8484.20130095","volume":"35","author":"JB de Alencar","year":"2013","unstructured":"de Alencar, J. B. et al. Importance of immune response genes in hemophilia A. Rev. Bras. Hematol. Hemoter. 35, 280\u2013286 (2013).","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"2268_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.clim.2007.01.005","volume":"123","author":"M Thewissen","year":"2007","unstructured":"Thewissen, M. et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin. Immunol. 123, 209\u2013218 (2007).","journal-title":"Clin. Immunol."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-02268-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-02268-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-02268-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T14:10:24Z","timestamp":1683727824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-022-02268-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2268"],"URL":"https:\/\/doi.org\/10.1038\/s41390-022-02268-5","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.L.-M. received a grant and research support from Pfizer and Novo Nordisk. G.K. received a grant and research support from Alnylam, Bayer, BPL, Opko Biologics, Pfizer, Shire, and honoraria for consultancy\/lectures from Alnylam, Bayer, CSL, Opko Biologics, Pfizer, Takeda, and ROCHE. Other authors have no relevant conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Children\u2019s parents gave informed consent for their child\u2019s participation in the study. The study was approved by the Ethics Committee of Sheba Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}